Store-A-Tooth has been available since 2006 from dentists across the U.S. At the core of our tooth transport device is the Save-A-Tooth device, which is FDA-approved and ADA accepted for the preservation of avulsed teeth. We use Save-A-Tooth for tooth collection and transport to ensure optimal viability of your sample for processing and cryopreservation. Our laboratory is FDA-registered, CLIA-certified, and AABB-accredited.
As the research community learns more and more about stem cells and dental stem cells specifically, our goal at Provia Labs is to make this information available to you so that you can make the most informed decisions possible. We welcome questions and feedback it helps us provide better information and services.
While at HCIT, he formed partnerships with global pharmaceutical companies as well as major academic medical institutions to standardize the management of donated human specimens by using advanced logistics and clinical data management software and protocols.
Prior to HCIT, Mr. Greenman led the strategic marketing function for Philips Medical System's Remote Patient Management Division, part of Philip's New Ventures organization. In this role, Mr. Greenman was responsible for commercialization and partnership strategy for a cardiovascular disease management platform technology.
Prior to Philips, Mr. Greenman was Director of Business Development for Ardais Corporation, a biorepository management company that set the standard in tissue banking bioethics, logistics, and quality by building one of the largest repositories of research quality commercially available cancer tissue in the world.
Mr. Greenman was the founder of medXtend Corporation, a venture backed healthcare services company providing medical devices and services for use by Radiologists and Primary Care Physicians. Additionally, Mr. Greenman worked in a variety of healthcare consulting roles within Accenture's Healthcare Practice, KPMG Peat Marwick's Healthcare Strategy Group, Oracle, and the Boston Consulting Group.
Dr. Verlander was most recently the Associate Director for Strategic Development of the Laboratory for Molecular Medicine (LMM) within the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics, where he helped transform the vision of personalized medicine into reality by translating research discoveries into breakthrough molecular diagnostic tests.
Dr. Verlander led the team that developed the first clinical test for detection of EGFR mutations predicting therapeutic response in lung adenocarcinoma. Dr. Verlander is a molecular geneticist with nearly 15 years of experience in various aspects of human genetics in both academia and industry, including research at The Rockefeller University in New York on the molecular genetics of Fanconi anemia (FA), a DNA breakage disorder leading to bone marrow failure and increased risk of leukemia.
At Optiva Corporation, designers of the Sonicare electric toothbrush, Bruce played an important role in educating dentists and patients globally about the importance of preventive dentistry and the role that good brushing habits and professional dental care play in ensuring healthy teeth and gums.
At Bausch & Lomb Inc, the global eye care company, he supported the launch of innovative new products, and helped to bring Bausch & Lomb products and services to eye care professionals and consumers in Europe, the Middle East and Africa.
He began his career at Organogenesis, Inc. where he developed and implemented pre-clinical investigations and subsequently managed all patient immunology safety testing leading to the PMA approval of Apligraf.
In 2002, he joined ViaCell, Inc. where he served as Director of Therapeutic Development and subsequently Senior Director of Analytical Biology. In these roles he oversaw strategic and operational scientific plans leading to successful approval of both IND and IDE FDA filings and completion of the companys cell therapy clinical trial.
As part of these efforts Dr. Laning managed numerous scientific joint ventures with Amgen, J&J, and Alnylam investigating combinatorial stem cell product development initiatives in cardiac repair and hematopoietic reconstitution. He subsequently brought his extensive experience in scientific management and product development to scientific and business consulting opportunities in industry and academics as Founder and Principal of JCLaning Bio-Consulting.
Most recently he joined the Massachusetts Human Stem Cell Bank and Registry as Executive Director eager to complete the important tasks required to develop the Bank & Registry into the world class resource envisioned at its inception. He received his BA in Biology from Boston University and his PhD in Immunology from Harvard University.
Clinically trained in the Department of Psychiatry at Harvard Medical School & the Massachusetts General Hospital, he earned his post-doctorate Masters in Public Health from the Harvard School of Public Health.
Over the last 35 years, Dr. Manganello has been an entrepreneur in multiple settings involving outpatient health care delivery, medical device company start-ups and international consulting to health care delivery systems.
She was inspired by the philanthropic efforts of her sister Dana Reeve, a non-smoker who died from lung cancer and her brother-in-law Christopher Reeve, the late actor, who had a passion for stem cell research for spinal cord injuries and other illnesses.
She is currently on the board of the National Cancer Institute and Lung Cancer Alliance and has spent the past 10 yearsas a biotech and pharmaceutical professional, and becoming a noted, inspirational speaker to families dealing with medical hardships.
Morosini joined Store-A-Tooth following her position with AstraZeneca Pharmaceuticals working in the area of research and development of cancer drugs and strategies. Additionally she has contributed to the development of a data element taxonomy (DET) of disease models for use by genomic researchers as part of the federal governments National Institute of Standards and Technology Program.
Dr. Curatola cofounded CS Bioscience Inc., a dental biotech company, and currently serves as its Chairman of the Board. The company performs research and development of pioneering natural therapeutics that promote oral health. In addition, Dr. Curatola is the founder of Rejuvenation Dentistry, a wellness-focused global network of dental practices, and the co-inventor and co-developer of REVITIN Oral Therapy. Dr. Curatola has private dental practices in both Manhattan and East Hampton, New York.
Prior, he was a founder of Ardais Corporation and co-developed the bioethical and legal frameworks under which the company worked with academic medical centers to bank 'human subjects' data and biospecimens that were then distributed to industry and academic researchers.
Dr. Paul Krasner, clinical professor of endodontics at Temple University School of Dentistry, received his D.D.S. from Temple University in 1971 and a Certificate in Endodontology from Kingsbrook Jewish Medical Center (New York) in 1975.
Dr.Perrotta is a member of American Dental Society, Massachusetts Dental Society, East Middlesex District Dental Society and the American Dental Implant Association and been involved with stem cell technology since 2005.
Dr. Jim Vaught spent 14 years (1999-2013) at the U.S. National Cancer Institute (NCI), most recently as the Chief of the Biorepositories and Biospecimen Research Branch (BBRB) in the Cancer Diagnosis Program.
He has been working in the field of biorepository and biospecimen science for over 20 years. In 1999, he was one of the founding members of the International Society for Biological & Environmental Repositories (ISBER) and was its second President.
He serves on a number of biobank advisory groups including the Telethon-Italy Genetic Biobank Network; the Stellenbosch University (Cape Town) H3-Africa Governance Advisory Panel; and the Biobanques Network (France) Scientific Board.
In addition to ISBER, Dr. Vaught is a member of the American Association for Cancer Research (AACR), the American Society for Pharmacology and Experimental Therapeutics, the European Society for Biopreservation & Biobanking and the American Association for Clinical Chemistry.